Trial record 2 of 8 for:
Dapansutrile
Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04540120 |
|
Recruitment Status :
Recruiting
First Posted : September 7, 2020
Last Update Posted : January 26, 2022
|
Sponsor:
Olatec Therapeutics LLC
Collaborator:
CTI Clinical Trial and Consulting Services
Information provided by (Responsible Party):
Olatec Therapeutics LLC
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | June 2022 |
| Estimated Study Completion Date : | July 2022 |